Acute nicotine administration in Alzheimer's disease: An exploratory EEG study

Neuropsychobiology

Volumn 41, Issue 4, 2000, Pages 210-220

  Knott, Verner ^a   Engeland, Christopher ^b   Mohr, Erich ^c   Mahoney, Colleen ^a   Ilivitsky, Vadim ^a  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c PRA International USA   (Netherlands)

Author keywords

Acetylcholine; Alzheimer's disease; Electroencephalography; Nicotine; Tetrahydroaminoacridine

Indexed keywords

CHOLINESTERASE INHIBITOR; NICOTINE; NICOTINE GUM; PLACEBO;

ADULT; AGED; ALPHA RHYTHM; ALZHEIMER DISEASE; ARTICLE; BETA RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTA RHYTHM; DEMENTIA; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THETA RHYTHM; VERTIGO;

EID: 0034097530     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026662     Document Type: Article

References (111)

1. McKinney M, Coyle J, Hedeen J: Topographic analysis of the innervation of the rat neocortex and hippocampus by basal forebrain cholinergic system. J Comp Neurol 1983;217:103-121.
2. Johnston M, McKinney M, Coyle J: Neocortical cholinergic innervation: A description of extrinsic components in the rat. Exp Brain Res 1991;43:159-172.
3. Wenk H, Volker B, Meyer U: Cholinergic projections from magnocellular nuclei of the basal forebrain to cortical area in rats. Brain Res Rev 1980;2:295-316.
4. Fibiger H: The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res Rev 1982;4:327-388.
5. Perry E, Perry R, Blessed G, Tomlinson B: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;i:189.
6. Perry E, Tomlinson B, Blessed G, Bergman K, Gibson P, Perry R: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2: 1457-1459.
7. Nordberg A, Alafuzoff I: Nicotine and muscarinic subtypes in the human brain: Changes with aging and dementia. J Neurosci Res 1992; 31:103-111.
8. Nordberg A, Adem A, Hardy J, Winblad B: Change in nicotine receptor subtypes in temporal cortex of Alzheimer brains. Neurosci Lett 1988;86:317-321.
9. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neurol Transm Park Dis Dement Sect 1990;2:215-224.
10. Nilsson L, Adem A, Hardy J, Winblad B, Nordberg A: Do tetrahydroaminoacridine and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J Neural Transm 1987;70:357-368.
11. Nordherg A, Anders L, Lundquist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M: Hellstrom-Lindhal E, Bjurling P, Fasth K-J, Langstrom B, Winblad B: Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992;13:747-758.
12. Davis K, Thal L, Gamzu E, Davis S, Woolfson R, Gracon S, Drachman D, Schneider L, Whitehouse P, Hoover T, Morris J, Kawas C, Knopman D, Earl N, Kumar V, Doody R: Tacrine collaborative study group: A double-blind, placebo-controlled multicenter study of Tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
13. Mohr E, Mendis T, Rusk I, Grimes D: Neurotransmitter replacement therapy in Alzheimer's disease. J Psychiatry Neurosci 1994;19: 17-21.
14. Giacobini E: From molecular structure to Alzheimer therapy. Jap J Pharmacol 1997;74:225-241.
15. Summers K, Cuadra G, Naritoku D, Giacobini E: Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex. Drug Dev Res 1994;31:108-119.
16. Schwarz R, Kellar K: Nicotinic cholinergic receptor binding sites in the brain: Regulation in vivo. Science 1983;220:214-220.
17. Romanelli L, Ohman B, Adem A, Nordberg A: Subchronic treatment of rats with nicotine: Interconversion of nicotine receptor subtypes. Eur J Pharmacol 1988;148:289-291.
18. 3H] nicotine binding sites in human brain. J Neurochem 1988;50:1243-1247.
19. Nybäck H, Nordberg A, Långström B, Halldin C, Åhlin A, Swahn C, Sedvall G: Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. Prog Brain Res 1987;79:313-319.
20. Nybäck H, Nordberg A, Åhlin S, Curvall M, Eriksson L: PET studies on the uptake of (S) and (R) [IIC] nicotine in the human brain: Difficulties in visualizing specific receptor binding in vivo. Psychopharmacology 1994;115:31-36.
21. Brenner D, Kukull W, van Belle G, Bowen J, McCormick W, Teri L, Larson E: Relationship between cigarette smoking and Alzheimer's disease in a population-based case-controlled study. Neurology 1993;43:293-300.
22. Salib E, Hillier V: A case-control study of smoking and Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:295-300.
23. Ott A, Slooter A, Hofman A, van Harskamp F, Witteman J, Van Brueckhaven C, van Duijn C, Breteler M: Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam study. Lancet 1998; 351:1840-1843.
24. Buccafusco J, Jackson W: Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in the young and aged monkeys. Neurobiol Aging 1991;12:233-238.
25. Widzowski D, Cregan E, Biolobok P: Effects of nicotinic agonist and antagonists on spatial memory in normal adult and aged rats. Drug Dev Res 1994;31:24-31.
26. Levin E: Nicotine systems and cognitive function. Psychopharmacology 1992;108:417-431.
27. Warburton D: Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:181-191.
28. Pritchard W, Robinson J: Effects of nicotine on human performance: in Snel J, Lorist M (eds): Nicotine, Caffeine and Social Drinking - Behavior and Brain Function. Amsterdam, Harwood Academic Publishers, 1998, pp 21-81.
29. Katayama S, Hirata K, Tanaka H, Yamazaki K, Fujikane M, Tchimaru Y: Efficacy of transdermal nicotine in dementia: A study using event-related potentials and a middle latency response; in Domino E (ed): Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, NPP Books, 1995, pp 289-302.
30. Newhouse P, Sunderland T, Narang P, Mellico A, Fertis J, Lawlor B, Murphy D: Neuroendocrine, physiologic and behavioural response following intravenous nicotine in non-smoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology 1990;15:471-484.
31. Newhouse P, Sunderland T, Turiot P, Blumbardt C, Weingartner H, Mellow A, Murphy D: Intravenous nicotine in Alzheimer's disease: A pilot study. Psychoneuroendocrinology 1988; 95:171-175.
32. Sahakian B, Jones G, Levy R, Gray J, Warburton D: The effects of nicotine on attention, information processing and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 1989;154:797-800.
33. Sahakian B, Coull J: Nicotine and tetrahydrominoacridine: Evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 1994;31:80-88.
34. Wesnes K: Nicotine increases mental efficiency: but how?; in Martin, Van Loon, Iwamoto, Davis (eds): Tobacco Smoking and Nicotine: A Neurobiological Approach. New York, Plenum Press, 1987, pp 63-80.
35. Conrin J: The EEG effects of tobacco smoking - A review. Clin Electroencephalogr 1984; 11:180-187.
36. Church R: Smoking and the human EEG: in Ney T, Gale A (eds): Smokers and Human Behavior. Chichester, Wiley and Sons, 1989, pp 115-140.
37. Knott V: A neuroelectric approach to the assessment of psychoactivity in comparative substance use; in Warburton D (ed): Addiction Controversies. London, Harwood Academic Publishers, 1990, pp 66-89.
38. Knott V, Harr A, Lusk-Mikkelsen S: The functional utility of smoking; in Snel J, Lorest M (eds): Nicotine, Caffeine and Social Drinking: Behaviour and Brain Function. Amsterdam, Harwood Academic Publishers, 1998, pp 115-130.
39. Knott V: Neuroelectrophysiological investigation into the smoking habit. Hum Psychopharmacology 1997;12:569-578.
40. Rosén I: Electroencephalography as a diagnostic tool in dementia. Dement Geriatr Cogn Disord 1997;8:110-116.
41. Agnoli A, Martucci N, Manna V, Conti L, Fioravanti M: Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: A neuropsychological and computerized electroencephalographic study. Clin Neuropharmacol 1983;6:311-323.
42. Saletu D: The use of pharmaco-EEG in drug profiling: in Hindmarch I, Stonier P (eds): Human Psychopharmacology: Measures and Methods. Chichester, Wiley and Sons, 1987, vol I, pp 173-200.
43. Saletu B: Neurophysiological aspects of aging and gerontopsychopharmacology: in Ban E, Lehmann H (eds): Diagnosis and Treatment of Old Age Dementias. Modern Problems in Pharmacopsychiatry. Basel, Karger, 1989, pp 43-59.
44. Saletu B: EEG/EP mapping in neurodegenerative and cognitive disorders: in Racagni G. Brunello N, Langer S (eds): Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. International Academy of Biomedical Drug Research. Basel, Karger, 1994, pp 24-30.
45. Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, Fischhol K, Litschauer G: EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis Assoc Dis 1991;5(suppl 1):S57-S75.
46. Saletu B, Anderer P, Paulus E, Rer Nat M, Heribert V, Semlitsch H, Grünberger J: Clinical diagnosis and treatment of adult-onset cognitive disorders: Electrophysiological approaches: in Cook T, Gershon S (eds): Diagnosis and Treatment of Adult-Onset Cognitive Disorders (AOCD). Old Saybrook, Psymark Communications, 1991, pp 102-137.
47. Alhainen K, Partanen J, Reinikainen K, Lavlumaa V, Soininen H, Airaksinen M, Riekkinen P: Discrimination of tetrahydroeminoacridine responders by a single dose pharmaco-EGG in patients with Alzheimer's disease. Neurosci Lett 1991:127:113-116.
48. Alhainen K, Riekkinen P: Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand 1993; suppl 149:16-22.
49. Riekkinen P Jr, Soininen H, Partanen J, Pääkkönen A, Helisalami S, Riekkinen P Sr: The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients. Psychopharmacology 1997;129:285-288.
50. Riekkinen P, Buzsaki G, Riekkinen M, Soininen H, Partanen J: The cholineric system and EGG slow waves. Electroencephalogr Clin Neurophysiol 1992;780:89-96.
51. Sunderland T, Tariot P, Newhouse P: Differential responsitivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 1998;13:371-389.
52. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
53. Folstein M, Folstein S, McHugh P: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. Psychiatry Res 1975;12:189-198.
54. John E, Prichep L, Fridman J, Easton P: Neurometrics: Computer-assisted differential diagnosis of brain dysfunctions. Science 1988;239: 162-169.
55. John E, Prichep L, Easton P: Normative data banks and neurometrics. Basic concepts, methods and results of norm constructions; in Gevins A, Rémond A (eds): Methods and Analysis of Brain Electrical and Magnetic Signals. EEG Handbook (revised series vol 1), Amsterdam. Elsevier Science, 1987, pp 449-495.
56. Matousěk M, Petersén I: Norms for the EEG: in Kellaway P, Petersén I (eds): Automation of Clinical Electroencephalography. New York, Raven Press, 1973, pp 75-102.
57. John ER, Prichep L, Trepetin M, Brown D, Kaye H: Developmental equations for the electroencephalogram. Science 1980;210:1255-1258.
58. Gasser T, Bacher P, Mochs J: Transformation towards the normal distribution of broadband spectral parameters of the EEG: Electroencephalogr Clin Neurophysiol 1982;53:119-124.
59. John ER, Pricep L, Friedman J, Essig-Peppard T: Neurometric classification of patients with different psychiatric disorders: in Samson-Dollfus D (ed): Statistics and Topography in Quantitative EEG. Paris, Elsevier, 1988, pp 88-95.
60. Yingling C, Galin D, Fein G, Peltzman D, Davenport L: Neurometrics does not detect 'pure' dyslexics. Electroencephalogr Clin Neurophysiol 1986;63:426-430.
61. Alvarez A, Pascual R,Valdes P: US EEG developmental equations confirmed for Cuban school children. Electroencephalogr Clin Neurophysiol 1987;67:330-332.
62. Harmony T, Alvarez A, Pascual R, et al: EEG maturation of children with different economic and psychosocial characteristics. Int J Neurosci 1987;31:103-113.
63. John ER, Prichep L, Ann H, et al: Neurometric Evaluation of Brain Function in Normal and Learning Disabled Children. Ann Arbor, University of Michigan Press, 1989.
64. Matsura M, Okubo Y, Toru M, et al: A cross-sectional study of children with emotional and behavioral problems: A WHO collaborative study in the western Pacific region. Biol Psychiatry 1993;34:59-65.
65. Prichep L, John E: QEEG profiles of psychiatric disorders. Brain Topogr 1992;4:249-257.
66. Delacour J, Bassant M-H, Onofrj M, Santucci V, Kleinlogel H: Group Report 7: Electrophysiological models for the study of cognitive enhancers. Pharmacopsychiatry 1990;23:90-93.
67. Duffy F, Hughes J, Miranda F, Bernad P, Cook P: Status of quantitative EEG (QEEG) in clinical practice, 1994. Clin Electroencephalogr 1994;25:6-21.
68. Schreiter-Gasser U, Gasser T, Ziegler P: Quantitative EEG analysis in early onset Alzheimer's disease: Correlation with severity, clinical characteristics, visual EEG and CCT. Electroencephalogr Clin Neurophysiol 1994;90: 267-272.
69. Hartikainen P, Soininen H, Parttanen J, Helkala E, Riekkinon P: Aging and spectral analysis of EEG in normal subjects: A link to memory and CSF AchE. Acta Neurol Scand 1992;86: 148-155.
70. Soininen H, Reinikainen K, Partanen J, Helkala E-L, Paljarvi L, Riekkinen P: Slowing of electroencephalogram and choline acetyltransferase activity in definitive Alzheimer's disease. Neuroscience 1992;49:529-535.
71. Riekkinen P, Riekkinen P Jr, Soininen H, et al: Regulation of EEG delta activity by the cholinergic nucleus basalis; in Maurer K, Riederer P, Beckmann H (eds): Alzheimer's Disease: Epidemiology, Neuropathology, Neurochemistry and Clinics. Wien, Springer-Verlag, 1990, pp 437-445.
72. Sirviö J, Kutvonen R, Hartikainen P, Riekkinen P: Cholinesterases in the cerebrospinal fluid, plasma and erythrocytes of patients with Alzheimer's disease. J Neural Transm 1989;75: 119-127.
73. Buzsaki G, Bickford R, Armstrong D, et al: Electric activity in the neocortex of freely moving young and aged rats. Neuroscience 1988; 26:735-744.
74. Riekkinen P Jr, Siviö J, Riekkinen P: Relationships between the cortical choline acetyltransferase content and EEG delta power. Neurosci Res 1990;8:12-20.
75. Riekkinen P Jr, Siviö J, Valjakka A, Pitkänen A, Partanen J, Riekkinen P: The effects of concurrent manipulations of cholinergic and noradrenergic systems on neocortical EEG and spatial learning. Behav Neural Biol 1990;54: 204-210.
76. Riekkinen P Jr, Siviö J, Jäkälä P, Lammintausta R, Riekkinen P: Interaction between the alpha-noradrenergic and muscarinic systems in the regulation of neocortical high voltage spindles. Brain Res Bull 1990;25:147-149.
77. Sannita W, Maggi L, Rosalini G: Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers. Neuropsychobiology 1987; 17:199-205.
78. Pickworth W, Fant R, Butschky M, Heming J: Effects of mecamylamine on spontaneous EEG and performance in smokers and non-smokers. Pharmacol Biochem Behav 1997;56:181-187.
79. Knott V, Harr A, Ilivitsky V: EEG correlates of acute nicotine and muscarinic cholinergic blockade: Separate and combined administration of mecamylamine and scopolamine in normal human subjects. Hum Psychopharmacol 1997;12:573-582.
80. Neufeld M, Rabey M, Parmet Y, Silfris P, Treves T, Korczyn A: Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. Electroencephalogr Clin Neurophysiol 1997;91:407-412.
81. Nuwer M: Quantitative EEG. I. Techniques and problems of frequency analysis and topographic mapping. J Clin Neurophysiol 1998;5: 1-43.
82. Knott V: Dynamic EEG changes during cigarette smoking. Neuropsychobiology 1988;19: 54-60.
83. Knott V: Effects of low-yield cigarettes on electroencephalographic dynamics. Neuropsychobiology 1989;21:216-222.
84. Knott V: Neuroelectric correlates of smoking behaviours; in Adlkofer F (ed): Effects of Nicotine on Biological Systems. Basel, Birkhäuser, 1990, pp 491-500.
85. Robinson J, Pritchard W, Davis R: Psychopharmacological effects of a cigarette with typical 'tar' and carbon monoxide yields but minimum nicotine. Psychopharmacology 1992;108: 466-472.
86. Domino E, Matsuoka S, Kadoya C: Variable EEG brain localization effects of tobacco smoking in relationship to plasma nicotine levels: in Domino E (ed): Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, NPP Books, 1995, pp 263-273.
87. Knott V: Brain electrical imaging the dose-response effects of cigarette smoking. Neuropsychobiology 1989;22:236-242.
88. Pickworth W, Herning R, Henningfield J: Electroencephalographic effects of nicotine chewing gum in humans. Pharmacol Biochem Behav 1986;25:879-882.
89. Knott V, Bosman M, Mahoney C, Ilivitsky V, Quirt K: Transdermal nicotine: Single dose effects on mood, EEG, performance and event-related potentials. Pharmacol Biochem Behav. in press.
90. Benowitz N: Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl Med 1988;319:1318-1330.
91. Knott V, Harr A: Assessing the topographic EEG changes associated with aging and acute/ long-term effects of smoking. Neuropsychobiology 1996;33:210-222.
92. Klimesch W: EEG-alpha rhythms and memory processes. Int J Psychophysiol 1997;26:319-340.
93. Clarke P: Nicotine receptor blockade therapy and smoking cessation. Br J Addict 1991;86: 501-505.
94. Le Houezec J, Benowitz N: Basic and clinical pharmacology of nicotine. Clin Chest Med 1991;12:681-699.
95. Pomerleau O, Pomerleau C: Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation. Neurosci Behav Rev 1984;8:503-513.
96. Stolerman L: Could nicotine antagonists be used in smoking cessation? Br J Addict 1986; 81:47-53.
97. Domino E: Electroencephalographic and behavioral arousal effects of small doses of nicotine: A neuropsychopharmacological study. Ann My Acad Sci 1967;142:216-244.
98. Kawamura H, Domino E: Different actions of M and N cholinergic agonists on the brain stem activating system. Int J Neuropharmacol 1969; 8:205-115.
99. Bringmann A: Nicotine affects the occipital theta rhythm after testing of the pedunclepontine tegmental nucleus in rats. Neuropsychobiology 1997;35:102-107.
100. Riekkinen P, Kuilunen J, Riekkinen M: Effects of thalamic and nucleus basalis infusions of nicotine on conical EEG. Neuroreport 1995;6:1625-1628.
101. Riekkinen P, Riekkinen M, Sirviö J: Effects of nicotine on neocortical electrical activity in rats. J Pharmacol Exp Ther 1993;267:776-784.
102. Knott V, Hooper C, Lusk-Mikkelsen S, Kerr C: Variation in spontaneous brain electrical (EEG) topography related to cigarette smoking: Acute smoking-drug comparisons, cholinergic transmission, individual differences and psychopathology; in Domino E (ed): Brain Imaging of Nicotine and Tobacco Smoking, Ann Arbor, NPP Books, 1995, pp 167-189.
103. Pickworth W, Herning R, Henningfield J: Mecamylamine reduces some EEG effects of nicotine chewing gum in humans. Pharmacol Biochem Behav 1988;30:149-153.
104. Knott V, Harr A, Ilivitsky V, Mahoney C: The cholinergic basis of the smoking-induced EEG activation profile. Neuropsychobiology 1998;38:97-107.
105. Perryman K, Fitten J: Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 1991;4:127-133.
106. Salmon D, Thal L, Butters N, Heindel W: Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental state examinations. Neurology 1990;337:1225-1230.
107. Herrmann W: Electroencephalography in Drug Research. New York, Stuttgart, 1982.
108. Kerr J, Sherwood N, Hindmarch I: Separate and combined effects of the social drugs on psychomotor performance. Psychopharmacology 1991;104:113-119.
109. Parrott A, Craig D, Haines M, Winder G: Nicotine polacrilex gum and sustained attention; in Adlkofor F (ed): Effects of Nicotine on Biological Systems. Advances in Pharmacological Sciences. Basel, Birkhäuser Verlag, 1991, pp 559-564.
110. Parrott A, Craig D: Cigarette smoking and nicotine gum (0, 2 and 4 mg): Effects upon four visual attention tasks. Neuropsychobiology 1992;25:35-43.
111. Sherwood N, Kerr J, Hindmarch I: Psychomotor performance in smokers following single and repeated doses of nicotine gum. Psychopharmacology 1992;108:432-436.